•  
  •  
 

ORCID ID

Aprilia Pratiwi Iriani Bahar: https://orcid.org/0009-0009-5022-2887

Sri Ratna Dwiningsih: https://orcid.org/0000-0003-2511-4920

Widjiati Widjiati: https://orcid.org/0000-0002-8376-1176

Sutrisno Sutrisno: https://orcid.org/0000-0003-1658-2992

Abstract

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, commonly characterized by elevated luteinizing hormone (LH) and decreased follicle-stimulating hormone (FSH) levels. These hormonal imbalances impair folliculogenesis and ovulation, often resulting in infertility. This study aimed to evaluate the effects of Biophytum petersianum (Kebar leaf) extract on LH levels and ovarian follicle development in a testosterone propionate-induced rat model of PCOS. A total of 30 adult female white rats (Rattus norvegicus) were randomly assigned to five groups: a negative control (K), a positive control with PCOS induction (K+), and three treatment groups (P1, P2, and P3) receiving daily oral doses of 0.47, 0.95, and 1.42 mg/kg of Kebar leaf extract, respectively. The authors measured serum LH levels using enzyme-linked immunosorbent assay (ELISA) and assessed ovarian histology microscopically to quantify follicular development. The group receiving 0.47 mg/kg (P1) demonstrated a significant reduction in LH levels (p = 0.01 vs. K+) and a higher number of healthy primary follicles (p = 0.02), indicating early follicular recovery. Moderate benefits were observed in the 0.95 mg/kg group (P2). Meanwhile, the highest dose (1.42 mg/kg, P3) was associated with reduced follicle counts, suggesting a potential biphasic or adverse effect at higher concentrations. Biophytum petersianum extract demonstrated dose-dependent benefits in regulating LH levels and supporting early folliculogenesis in a PCOS rat model. These findings suggest its potential as a complementary herbal therapy for hormonal and reproductive dysfunction in PCOS. Therefore, further studies are required to explore its molecular mechanisms and long-term efficacy.

Keywords

Chronic disease; maternal health; reproductive health; reproductive health care; sexual and reproductive health care

First Page

70

Last Page

78

DOI

10.65346/2599-056X.2431

Publication Date

6-30-2026

Share

COinS